Neoplasm of Uncertain Histogenesis

This study from 1991 (before the advent of next-generation sequencing) aimed to decipher molecular basis and oncogenic mechanisms of the t(1;19)(q23;p13), which was already known at the time as a rec… (full text at CIViC)

PMID 1671560 · Hunger et al., 1991 · Open in CIViC

From 1101 patients enrolled in 4 consecutive acute lymphoblastic leukemia clinical trials at St Jude Children's Research Hospital (1979-1994), 45 of them were identified to bear t(1;19)(q23;p13) or d… (full text at CIViC)

PMID 7989935 · Pui et al., 1994 · Open in CIViC

In an earlier study of 15 patients with TCF3::PBX1 B-ALL, 2 of the 15 had neonatal blood spots found to be positive for the TCF3::PBX1 fusion breakpoint using polymerase chain reaction (PCR). In this … (full text at CIViC)

PMID 31434706 · Hein et al., 2019 · Open in CIViC

While it is not common in adult acute lymphoblastic leukemia (ALL), the t(1;19)(q23;p13) rearrangement is still a hallmark for favorable prognosis in a retrospective cohort study with 427 adult patien… (full text at CIViC)

PMID 32955970 · Yilmaz et al., 2021 · Open in CIViC

Clinical trials conducted at St Jude Children's Research Hospital revealed that patients with pre-B acute lymphoblastic leukemia who have the TCF3::PBX1 fusion exhibit a favorable overall outcome when… (full text at CIViC)

PMID 19282835 · Jeha et al., 2009 · Open in CIViC

In an in vitro kinase study, the recombinant TEK R849W mutant kinase demonstrated resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 77 and 35) when compared to wild type… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The TERF2-JAK2 fusionis rare. This study was cond… (full text at CIViC)

PMID 27894077 · Boer et al., 2017 · Open in CIViC

In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

In patients with acral lentiginous melanoma, those with amplification of TERT had shorter overall survival.

PMID 25219713 · Diaz et al., 2014 · Open in CIViC

In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no muta… (full text at CIViC)

PMID 25024077 · Xing et al., 2014 · Open in CIViC

In 308 thyroid fine-needle aspiration biopsies, 0 of the 179 benign tumors displayed either the C228T or the C250T TERT promoter mutation; however, 9 of the 129 differentiated thyroid cancers had eith… (full text at CIViC)

PMID 25121551 · Liu et al., 2014 · Open in CIViC

TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspo… (full text at CIViC)

PMID 23955565 · Nonoguchi et al., 2013 · Open in CIViC

A total of 96 histopathologically confirmed RCC cases and corresponding normal tissues were subjected to hTERT gene expression using real-time PCR. Two RCC cell lines viz. ACHN and A498 were treated w… (full text at CIViC)

PMID 28215740 · Pal et al., 2017 · Open in CIViC

In 187 patients with glioblastoma, those with TERT promoter mutations had worse cummulative survival than wild-type patients. The most common mutation was C228T (73% of mutants) followed by C250T (27%… (full text at CIViC)

PMID 23955565 · Nonoguchi et al., 2013 · Open in CIViC

Patients with mutations at TERT promoter region of -124 and -146 of ATG showed poor survival in the absence but not in the presence of the variant allele of a common polymorphism with ID of rs2853669 … (full text at CIViC)

PMID 24101484 · Rachakonda et al., 2013 · Open in CIViC

In a retrospective study on TCGA data, the presence of non-synonymous mutations in TET1 is enriched in patients responding to immune checkpoint inhibitor treatment (n=519, P = 0.003). In an ICI-treate… (full text at CIViC)

PMID 31623662 · Wu et al., 2019 · Open in CIViC

In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death… (full text at CIViC)

PMID 22430270 · Gaidzik et al., 2012 · Open in CIViC

In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations.

PMID 19666869 · Kosmider et al., 2009 · Open in CIViC

Mutations in this gene have been described in several genome-wide studies

PMID 30617194 · Grande et al., 2019 · Open in CIViC

This study evaluates 200 nephrectomy cases. Within the 200 cases, there are four cases that are Xp11.2 translocation renal cell carcinomas (RCC). Previous studies identified two stages (pediatric and … (full text at CIViC)

PMID 34917511 · Ge et al., 2021 · Open in CIViC

This manuscript is a study of 37 TFEB-altered tumors, 15 of which are associated with TFEB amplification at 6p21.1 and 22 of which are associated with TFEB-rearrangement. Previous literature had indic… (full text at CIViC)

PMID 31600176 · Gupta et al., 2019 · Open in CIViC

TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort. TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethim… (full text at CIViC)

PMID 25900183 · May et al., 2015 · Open in CIViC

An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PTEN and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that PTEN knockdown cells (achieved via … (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC)

PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC

Genes not previously reported to be significantly mutated in PCa, such as cell division cycle 27 homolog (Saccharomyces cerevisiae) (CDC27), myeloid/lymphoid or mixed-lineage leukemia 3 (MLL3), lysine… (full text at CIViC)

PMID 23265383 · Lindberg et al., 2013 · Open in CIViC

172 patients treated with neoadjuvant concurrent chemoradiotherapy (CCRT) were retrospectively analyzed for expression of thrombospondin 2 (THBS2) using IHC (discovery set with 46 rectal cancer patien… (full text at CIViC)

PMID 26807188 · Lin et al., 2015 · Open in CIViC

TIMP1 overexpression was associated with resistance to fulvestrant in breast cancer cell lines.

PMID 23881388 · Bjerre et al., 2013 · Open in CIViC

High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy. High TIMP1 levels were … (full text at CIViC)

PMID 22544540 · Zhu et al., 2012 · Open in CIViC

TLK2 inhibition selectively inhibits the growth of TLK2-high breast cancer cells, downregulates ERα, BCL2 and SKP2, impairs G1/S cell cycle progression, induces apoptosis and significantly improves pr… (full text at CIViC)

PMID 27694828 · Kim et al., 2016 · Open in CIViC

TLX3, also known as HOX11L2 is a homeobox gene, located on the long arm of chromosome 5. TLX3 is not expressed in normal T-cell development. In this paper, the authors described a "new" cryptic transl… (full text at CIViC)

PMID 11587205 · Bernard et al., 2001 · Open in CIViC

The use of circulating tumor DNA in blood for TMB assessment was tested. The cancer gene panel NCC-GP150, which covers the whole exon regions of 150 genes, was created and tested for correlation again… (full text at CIViC)

PMID 30816954 · Wang et al., 2019 · Open in CIViC

This study examined ovarian cancer patients from The Cancer Genomics Atlas totaling 432 patient profiles. Patients were grouped into low and high tumor mutational burden (TMB) groups to examine the pr… (full text at CIViC)

PMID 33189611 · Fan et al., 2020 · Open in CIViC

In patients with initially low-grade IDH-mutant gliomas previously treated with temozolomide, a high tumor mutational burden (TMB-high)/temozolomide-associated hypermutator phenotype was associated wi… (full text at CIViC)

PMID 33823014 · Yu et al., 2021 · Open in CIViC